Raremark appoints Nicki Grundy as CFO

pharmafile | January 20, 2021 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Raremark, a global healthtech company specialising in rare disease, has appointed Nicki Grundy as Chief Financial Officer.

As a key member of Raremark’s senior leadership team, Grundy will take the lead on the company’s financial vision, strategic financial planning, and compliance.

Grundy has over 20 years of experience driving growth in businesses including CrownBio, Exco InTouch, and most recently Peppermint Technology, a legal software company.

The new appointment is part of a wider move to strengthen the company’s senior leadership team that saw Jeremy Edwards become CEO in 2020, along with Alex Garner who was promoted to COO.

Grundy herself said: “I’m thrilled to join the team at such a pivotal time, the growth the company is experiencing is phenomenal and I’m looking forward to helping take it to the next level. The industry is evolving rapidly and the services Raremark delivers through the Xperiome platform are truly unique with the potential to disrupt and challenge rare disease R&D.” 

Edwards, CEO of Raremark, added: “Taking on someone with Nicki’s calibre will help move us to an exciting new phase in the business. Her expert leadership and breadth of experience will be integral in helping us drive commercial growth in the rare disease space, and ultimately aid pharma in developing better rare disease therapies to improve patient lives.”

Related Content

No items found

Latest content